PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jkneurosocJournal of Korean Neurosurgical SocietyJournalInstructions for AuthorsOn-line Submission
 
J Korean Neurosurg Soc. 2010 July; 48(1): 14–19.
Published online 2010 July 31. doi:  10.3340/jkns.2010.48.1.14
PMCID: PMC2916143

Loss of Heterozygosity at 1p, 7q, 17p, and 22q in Meningiomas

In Bok Chang, M.D., Ph.D.,1 Byung Moon Cho, M.D., Ph.D.,corresponding author1 Seung Myung Moon, M.D., Ph.D.,1 Se Hyuck Park, M.D., Ph.D.,1 Sae Moon Oh, M.D., Ph.D.,1 and Seong Jin Cho, M.D., Ph.D.2

Abstract

Objective

Allelic losses or loss of heterozygosity (LOH) at many chromosomal loci have been found in the cells of meningiomas. The objective of this study was to evaluate LOH at several loci of different chromosomes (1p32, 17p13, 7q21, 7q31, and 22q13) in different grades of meningiomas.

Methods

Forty surgical specimens were obtained and classified as benign, atypical, and anaplastic meningiomas. After DNA extraction, ten polymorphic microsatellite markers were used to detect LOH. Medical and surgical records, as well as pathologic findings, were reviewed retrospectively.

Results

LOH at 1p32 was detected in 24%, 60%, and 60% in benign, atypical, and anaplastic meningiomas, respectively. Whereas LOH at 7q21 was found in only one atypical meningioma. LOH at 7q31 was found in one benign meningioma and one atypical meningioma. LOH at 17p13 was detected in 4%, 40%, and 80% in benign, atypical, and anaplastic meningiomas, respectively. LOH at 22q13 was seen in 48%, 60%, and 60% in benign, atypical, and anaplastic meningiomas, respectively. LOH results at 1p32 and 17p13 showed statistically significant differences between benign and non-benign meningiomas.

Conclusion

LOH at 1p32 and 17p13 showed a strong correlation with tumor progression. On the other hand, LOH at 7q21 and 7q31 may not contribute to the development of the meningiomas.

Keywords: Chromosome, Loss of heterozygosity, Meningiomas

INTRODUCTION

Since the introduction of Giemsa staining to distinguish between open and compact chromosome regions in the early 1970's, many cytogenetic approaches have been developed during the last three decades25). Loss of heterozygosity (LOH) analyses, such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization, have been used for localizing tumor suppressor genes in different grades of meningiomas12). LOH leading to inhibition of tumor suppressor genes has been shown to be one of the mechanisms of tumor development4,34).

The allelic loss or LOH of various chromosomal regions in meningiomas, including chromosomes 1p, 3q, 6q, 10q, 17p, 18p, 18q, and 22q, has been reported12). Among them, the loss of allelic regions in the long arm of chromosome 22 was the most prominent, found in 40-70% of meningiomas1,30).

HGF/cMET signaling has been shown to play an important role in oncogenesis in many human cancers, including human papillary renal cancer, ovarian cancer, childhood hepatocellular carcinoma, and gastric cancer19). The human Met and HGF receptor genes are located at 7q21 and 7q3115). However, there have only been a few reports relating the signaling of these genes to the formation and progression of meningiomas2,17). The objectives of this study were to evaluate LOH in several chromosomes in which LOH is seen frequently 17p13 related with mutation of p53 tumor suppressor gene, 7q21, 7q31, and 22q13 in different grades of meningiomas and to correlate the findings with various clinicopathological factors9,29).

MATERIALS AND METHODS

This study was approved by the Institutional Research Board (number : 10-022). Patients who had undergone total resection of a meningioma (Simpson grade I or II) between January 2000 and December 2004 were selected for the study. The authors could obtain tumor specimen and normal tissue of meninges during operations. Forty paraffine-embedded surgical specimens from these patients were obtained. After pathological interpretation of hematoxylin and eosin (H&E) stained slides, all tumors were classified as benign, atypical, or anaplastic meningiomas according to World Health Organization (WHO) classification11,16). Medical and surgical records, as well as pathologic findings, were reviewed retrospectively.

DNA extraction

All specimens were fixed in 10% formaldehyde and paraffin-embedded slices were obtained. Forty paraffin-embedded tumors were examined. Serial sections of 5 µm thickness containing tumor and non-tumor portions (normal tissue of meninges) were performed on each surgical specimen. After staining with H&E, the sections were microdissected to obtain an extract of deoxyribonucleic acid (DNA). Microdissected tissues were then deparaffinized in xylene for 1-2 hours. To extract DNA from specimens, the selected tissues were placed in 1.5 mL of digestion buffer (100 mM Tris-HCL, pH 8.0; 1% Tween 20, and 0.1 mg/mL proteinase K) at 52[degree celsius] for two days. After digestion, proteinase K was inactivated by incubation at 96[degree celsius] for 10 min and the samples were centrifuged at 14,000 rpm for 30 min. The extracts (about 2 µL) were used as template DNA for polymerase chain reaction (PCR).

LOH analysis and decision

total of ten polymorphic microsatellite markers were used : D1S193 and D1S463 for chromosome 1p32, D7S660 and D7S492 for 7q21, D7S486 and D7S655 for 7q31, D17S796 and TP53 for 17p13, and D22S193 and D22S929 for 22q13. Commercially available primers for these markers were used (GIBCO Inc., Carlsbad, CA, USA). The genomic sequences of the primers are listed in Table 1. PCR was carried out in a thermal cycler (Perkin Elmer Cetus 9700, USA). PCR amplifications were performed using 2 µL of DNA template, 0.25 µL of each primer, 1.25 mM NTP with 1/2dCTP, 1.5 mM MgCl2, 0.6 U Taq polymerase (0.07 µL), and 10× PCR buffer. Every cycle consisted of denaturation at 94[degree celsius] for 30 seconds, annealing at 55-60[degree celsius] for 30s, and extension at 72[degree celsius] for 40s, followed by a final extension at 72[degree celsius] for 10 min. Amplified PCR products (3 µL) were analyzed by 12% polyacrylamide gel electrophoresis. Using silver staining, the gain or loss of heterozygosity was assessed. The band intensity of two alleles in each case was determined visually. For a questionable allelic loss, the intensity was measured by densitometric analysis (Pharmacia, San Francisco, CA, USA).

Table 1
DNA sequences of primers used to detect LOH

LOH was assigned if there was a decrease in signal intensity greater than 50% in the tumor tissue allele compared to that of the corresponding non-tumor tissue allele. In this study, specimens scored as homozygote, not amplified, or not informative were excluded.

Statistical analysis

Statistical analysis was performed using the SAS® system. Chi-square test and Fisher's exact test were used to analyze the relationship between LOH of each chromosome and age, tumor location, grade, and histological types. A p-value of less than 0.05 was considered statistically significant.

RESULTS

Of 40 patients, there were 27 females and 13 males and the mean age was 44 years with a range of 27-67. Twenty-five benign, 10 atypical, and 5 anaplastic meningiomas were identified. The locations of tumors were 22 in the convexity, 7 in the parasagittal area, 6 in the falx, 3 in the lateral ventricle, and 2 in the sphenoidal ridge. Histological subtypes of 25 benign meningiomas consisted of 17 meningotheliomatous, 4 transitional, 3 fibrous, and 1 psammomatous type. The clinical and experimental data were described in Table 2.

Table 2
Clinical and experimental data of LOH in 40 cases of meningiomas

Frequency of LOH according to the grades

LOH at loci 1p32, 7q21, 7q31, 17p13 and 22q13 was detected in 15 (37.5%), 1 (2.5%), 2 (5%), 9 (22%), and 21 (52.5%) cases of meningiomas, respectively (Table 3). Identification of LOH at 1p32 was made in 24% of benign, 60% of atypical and 60% of anaplastic meniniomas, respectively. The authors classified grades as benign and non-benign (atypical or anaplastic) to assess statistical significance, and there was a significant relationship between benign and non-benign meningiomas and LOH at 1p32 (p = 0.0228) (Fig. 1). Whereas LOH at 7q21 was found in only one atypical meningioma, LOH at 7q31 was seen in one benign meningioma and one atypical meningioma. No significant correlations were identified between benign and non-benign meningiomas at 7q21 and 7q31. LOH on 17p13 was detected in 4%, 40%, and 80% of benign, atypical, and anaplastic meningiomas, respectively (Fig. 1). LOH on 22q13 was detected in 48%, 60%, and 60% of benign, atypical, and anaplastic meningiomas, respectively. LOH results at 17p13 showed a statistically significant difference between benign and non-benign meningiomas (p = 0.0006). However, there was no significance at 22q13 (p = 0.461).

Fig. 1
LOH at chromosomes 1p32 and 17p13. Representative D1S193 at 1p32 (A) and TP53 at 17p13 (B) microsatellite analysis of normal (N) and tumor (T) samples. The bottom band of each tumor lanes shows loss appearance (arrow).
Table 3
LOH of 1p32, 7q, 17p13, and 22q13 according to the clinicopathological factors in meningiomas

Frequency of LOH according to the histological subtypes

Of 25 benign meningiomas, excluding 10 atypical and 5 anaplastic meningiomas, identification of LOH at 1p32, according to histological subtypes, was seen 4 (23.5%) in meningothelial, 1 (33.3%) fibrous, and 1 (25%) in transitional type. In the case of 7q31 and 17p13, LOH was detected 1 (5.3%) in meningothelial type, respectively. Eight cases (47%) of meningothelial and 3 cases (75%) of transitional meningiomas showed LOH at 22q13 (p = 0.399). There were no statistical correlations between subtypes and LOH in any of the chromosomal regions examined in this study.

DISCUSSION

Since the identification of monosomy of chromosome 22, the molecular studies of meningiomas and gliomas have advanced in accordance with various cytogenetic developments13,33). LOH examined in this study led to the discovery of a tumor suppressor gene. The analysis of LOH using microsatellite probes has been reported in many tumors, especially malignant tumors32). In meningiomas, many authors have revealed deletions in various chromosomes using LOH analysis. Of them, the most common site of LOH was chromosome 22, followed by chromosome 1p.

The characteristic findings of this study were : 1) the detection of LOH was higher at 1p and 22q (24% and 48%, respectively) than that of at 7q21, 7q31 and 17p3 (0%, 4%, and 4%, respectively) in benign meningiomas, 2) LOH was most frequently detected at 22q13 and there was a significant difference of LOH between benign and non-benign meningiomas at 1p32 and 17p13.

Neurofibromatosis type 2 (NF 2) is a tumor suppressor gene on chromosome 22q, which has been implicated in the development of benign meningiomas27). NF2 gene mutations occur with a similar frequency between benign and non-benign (atypical or anaplastic) meningiomas, which suggests that NF2 is associated with meningioma initiation rather than progression27). According to Weber et al.31), the initial event of meningioma formation was related to an allelic loss at 22q. LOH at 1p, 6q, 10, 14q, and 18q, and gains in 1q, 9q, 12q, 15q, 17q, and 20q were associated with atypical meningiomas. As reported by Kim et al.10), LOH at 22q was seen in 47% of benign and in 100% of anaplstic meningiomas and there was a statistically significant correlation between the two groups. In addition, Lee et al.12) reported that 12.5-64% of benign meningiomas showed LOH of 22q and anaplastic meningiomas demonstrated 100% LOH on chromosome 22. In our study, LOH at 22q13 of benign meningiomas was 48%, which was similar to the results of other studies. In anaplastic meningiomas, however, LOH at 22q was 60%, and there was no significant correlation between two groups. This finding implies that LOH at 22q is related to tumorigenesis more so than tumor progression.

LOH at 1p is the second most frequent chromosomal abnormality in meningiomas and has been shown to be associated with meningioma progression21,28). The detection rate of LOH in 1p is 21-33% in benign and 71-85% in anaplastic meningiomas14,29). Leuraud et al.14) stated that LOH at 1p occurs after the loss of chromosome 22 and is more frequent in grade 2 than grade 1 meningiomas. In our study, LOH at 1p occurred more frequently in non-benign than in benign meningiomas, and in the transitional type more than in the meningothelial type. There was a significant correlation in grades, but no statistical association in histological subtypes (p = 0.02 and p = 0.18, respectively).

P53 gene located on chromosome 17p is a tumor suppressor gene and has been found to have mutations in most human cancers6,22). Mutations of p53 gene in human meningiomas have been reported in 7-13% of these tumors8,23). According to the report of Pykett et al.26), however, there was lack of elevated p53 protein levels in 16 primary meningiomas. There were few reports about LOH at 17p10,18). Kim et al.10) reported that LOH at 17p was identified in only two anaplastic meningiomas. In our study, LOH at 17p was seen with very low frequency in benign meningiomas (4%) and 80% of anaplastic meningiomas showed LOH. Also, there was a significant association between LOH at 17p and the grade of the tumor (p = 0.0006). Although we do not have data about the frequency of p53 gene somatic mutation, the findings of our study suggest that LOH at 17p might be associated with tumor progression in human meningiomas.

The hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotrophic protein secreted by mesenchymatous cells, which has been identified as a potent mitogen for hepatocytes3,19). The c-Met gene has been identified as a protooncogene in human osteogenic sarcoma and serves as a receptor for HGF/SF5,7). HGF/SF and c-MET are located on chromosome 7q15,24). HGF and c-MET are associated with oncogenesis in many human cancers and co-expressed in meningiomas19,20). A relationship between co-expression of HGF/c-MET and recurrence in meningiomas has been reported17). Accordingly, the authors wanted to identify whether or not LOH at 7q is related to meningioma recurrence. However, LOH at 7q21 and 7q31 was seen at very low frequencies in our study (2.5% and 5%, respectively).

CONCLUSION

This study suggests LOH at 22q13 may contribute to meningeal tumorigenesis and LOH at 1p32 and 17p13 may be associated with tumor progression. However, LOH at 7q21 and 7q31 may not contribute to the development of meningiomas. Nevertheless, to determine the relationship between LOH at 7q and meningiomas, further studies are necessary.

References

1. Akagi K, Kurahashi H, Arita N, Hayakawa T, Monden M, Mori T, et al. Deletion mapping of the long arm of chromosome 22 in human meningiomas. Int J Cancer. 1995;60:178–182. [PubMed]
2. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002;94:3210–3218. [PubMed]
3. Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, et al. Scatter factor and hepatocyte growth factor : activities, properties, and mechanism. Cell Growth Differ. 1992;3:11–20. [PubMed]
4. Bozzetti C, Bortesi B, Merisio C. Loss of heterozygosity (LOH) in ovarian cancer. Int J Gynaecol Obstet. 2004;85:294–295. [PubMed]
5. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29–33. [PubMed]
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53. [PubMed]
7. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol. 1996;16:1115–1125. [PMC free article] [PubMed]
8. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumors : an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol (Berl) 1993;85:611–616. [PubMed]
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304–6311. [PubMed]
10. Kim JH, Lee SH, Rhee CH, Park SY, Lee JH. Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. J Neurooncol. 1998;40:101–106. [PubMed]
11. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–225. discussion 226-219. [PubMed]
12. Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT, Jr, Omalu B. Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery. 2004;55:1163–1173. [PubMed]
13. Lee SH, Kim JH, Rhee CH, Kang YS, Lee JH, Choi KS. Loss of heterozygosity on chromosome 10, 13, 17, and p53 gene mutation in human brain gliomas. J Korean Neurosurg Soc. 1993;22:537–550.
14. Leuraud P, Marie Y, Robin E, Huguet S, He J, Mokhtari K, et al. Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas. J Neurooncol. 2000;50:207–213. [PubMed]
15. Liu Y. The human hepatocyte growth factor receptor gene : complete structural organization and promoter characterization. Gene. 1998;215:159–169. [PubMed]
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. [PMC free article] [PubMed]
17. Martínez-Rumayor A, Arrieta O, Guevara P, Escobar E, Rembao D, Salina C, et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett. 2004;213:117–124. [PubMed]
18. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1991;6:1313–1318. [PubMed]
19. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13:41–59. [PubMed]
20. Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S, Goya T, et al. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett. 1998;124:149–155. [PubMed]
21. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel WI, Zang KD. Loss of alkaline phosphatase activity in meningiomas : a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol. 1997;56:879–886. [PubMed]
22. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705–708. [PubMed]
23. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in nonastrocytic human brain tumors. Cancer Res. 1991;51:6202–6205. [PubMed]
24. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, et al. Mechanism of met oncogene activation. Cell. 1986;45:895–904. [PubMed]
25. Patil SR, Merrick S, Lubs HA. Identification of each human chromosome with a modified Giemsa stain. Science. 1971;173:821–822. [PubMed]
26. Pykett MJ, Landers J, George DL. Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas. J Neurooncol. 1997;32:39–44. [PubMed]
27. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006;5:1045–1054. [PubMed]
28. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas : a genetic model of meningioma progression. Cancer Res. 1995;55:4696–4701. [PubMed]
29. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas : correlation with increased morbidity. Cancer Res. 1998;58:3226–3230. [PubMed]
30. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res. 1999;59:5995–5998. [PubMed]
31. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas : toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A. 1997;94:14719–14724. [PubMed]
32. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, et al. A second-generation linkage map of the human genome. Nature. 1992;359:794–801. [PubMed]
33. Zankl H, Zang KD. Cytological and cytogenetical studies on brain tumors 4 Identification of the missing G chromosome in human meningiomas as no 22 by fluorescence technique. Humangenetik. 1972;14:167–169. [PubMed]
34. Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH. Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J Gastroenterol. 2004;10:1431–1435. [PubMed]

Articles from Journal of Korean Neurosurgical Society are provided here courtesy of The Korean Neurosurgical Society